Wunchana Seubwai^*†‡, Kulthida Vaeteewoottacharn^‡§, Ratthaphol Kraiklang^¶, Kazuo Umezawa^#, Seiji Okada^**, Sopit Wongkham^‡§

Oncology Research, Vol.23, No.1-2, pp. 21-28, 2015, DOI:10.3727/096504015X14424348426071

Abstract Cholangiocarcinoma (CCA) is a dismal cancer. At present, there is no effective chemotherapeutic regimen for CCA. This may be due to the marked resistance of CCA to chemotherapy drugs, for which a mechanism remains unknown. Nuclear factor-kB (NF-kB) is constitutively activated in a variety of cancer cells, including CCA. It has been shown to play roles in growth, metastasis, and chemoresistance of cancer. In the present study, we examined whether NF-kB is involved in the chemoresistance of CCA and whether dehydroxymethylepoxyquinomicin (DHMEQ), an effective NF-kB inhibitor, can overcome the drug resistance of CCA. Two CCA… More >

Hongtao Ren^*, Zhongwei Wang^*, Shuqun Zhang^*, Hongbing Ma^*, Yali Wang^*, Lijun Jia^*, Yiming Li^†

Oncology Research, Vol.23, No.5, pp. 249-256, 2015, DOI:10.3727/096504016X14562725373716

Abstract Interleukin-17A (IL-17A) plays a significant role in many inflammatory diseases and cancers. The aim of this study is to investigate the effect of IL-17A on the invasiveness of colorectal cancer. In the study, we found that IL-17A could promote the migration and invasion of colorectal cancer cells. Furthermore, after being treated with IL-17A, the expression and activity of matrix metalloproteinase 2 (MMP-2) and MMP-9 were upregulated. Moreover, the nuclear/overall fractions and DNA-binding activity of p65 and p50 were dramatically elevated by IL-17A. Pretreatment with a nuclear factor-kB (NF-kB) inhibitor (PDTC) or PI3K/AKT inhibitor (LY294002) was More >